	US 12,453,786 B2
	Radiomics-based treatment decision support for lung cancer
Robert J. Gillies, Tampa, FL (US); Matthew B. Schabath, Tampa, FL (US); and Wei Mu, Tampa, FL (US)
Assigned to H. Lee Moffitt Cancer Center and Research Institute Inc., Tampa, FL (US)
Appl. No. 17/757,017
Filed by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC., Tampa, FL (US)
PCT Filed Dec. 7, 2020, PCT No. PCT/US2020/063566 § 371(c)(1), (2) Date Jun. 8, 2022, PCT Pub. No. WO2021/118918, PCT Pub. Date Jun. 17, 2021.
Claims priority of provisional application 62/945,463, filed on Dec. 9, 2019.
Claims priority of provisional application 63/013,830, filed on Apr. 22, 2020.
Prior Publication US 2023/0038185 A1, Feb. 9, 2023
Int. Cl. A61K 51/04 (2006.01); A61B 6/00 (2006.01); A61P 35/00 (2006.01); G06N 3/045 (2023.01); G06N 3/082 (2023.01); G06V 10/44 (2022.01); G06V 10/82 (2022.01)

CPC A61K 51/0491 (2013.01) [A61B 6/5235 (2013.01); A61P 35/00 (2018.01); G06N 3/045 (2023.01); G06N 3/082 (2013.01); G06V 10/454 (2022.01); G06V 10/82 (2022.01)]

8 Claims

1. A method for treating a subject with a lung cancer, comprising

(a) administering to the subject ¹⁸F-FDG;

(b) imaging the ¹⁸F-FDG in the subject with positron emission tomography (PET) integrated with computed tomography (CT) and Magnetic Resonance Imaging (MRI) to produce ¹⁸F-FDG PET/CT and ¹⁸F-FDG PET/MRI images of the tumor;

(c) producing fusion images of the ¹⁸F-FDG PET/CT and ¹⁸F-FDG PET/MRI images using Kullback Leibler Divergence (KLD) criteria to identify KLD features;

(d) calculating texture features from the KLD fusion images;

(d) generating a radiomic signature from the identified texture features;

(f) computing a radiomic score based on the radiomic signature that is predictive of immunotherapy responsiveness and/or EGFR-Tyrosine kinase inhibitor (TKI) sensitivity; and

(g) treating the subject with an immune-checkpoint blockade immunotherapy; EGFR-TKI therapy; or chemotherapy and/or radiation therapy based on the radiomic score.